Abstract: Described herein are systems and methods for automatically building automations from desktop recordings using program synthesis. The problem of building automations for desktop applications can be lifted to a generalized concept of automations that operate on worlds whose “world state” can change asynchronously to the actions of the automation. Advantageously, in contrast with synthesis systems that take input-output demonstrations to synthesize a function that maps between them, the method presented here can synthesize from time-series traces of actions to automations that generalizes each step.

Abstract: The present invention describes photoluminescent apparatuses or colour filters (100a,100b,100c,100d) and methods (1000a,1000b) for manufacturing. A photoluminescent (PL) or quantum dot (QD) material (100) fills a pattern of trenches (40,42) formed on a surface or on opposite surfaces of an optically transparent substrate (20), being cured and sealed by an optically transparent cover (22); in another embodiment, the PL or QD material (100) are cured and sealed when two patterned optically substrates (20) are bonded together. Sealing of the PL or QD material in the trenches (40,42) preserves the optical and performance stability of these colour filters. These colour filters (100a, . . . 100d) are suitable for use in next generation UHD display screens or lighting applications.

Abstract: Methods and arrangements for effecting authentication in a secure transaction. There are defined, on behalf of a user, individuals who are members of a social network of the user. There is received, from the user, a transaction request for a secure transaction. An authentication test is conducted with the user and, upon meeting a predetermined requirement of the authentication test, the transaction request is validated. The authentication test requests the user to confirm at least one information item related to at least one member of the user's social network. Other variants and embodiments are broadly contemplated herein.

Abstract: The present invention relates to orally administered liquid pharmaceutical compositions of eslicarbazepine. The liquid compositions are in the form of ready to use suspension and suspension powder for reconstitution. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile and pH. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide physician with providing a more convenient and less cumbersome posology.

Abstract: Systems, methods, and devices for high-throughput data ingestion from a plurality of disparate and independent sources, and decentralized normalization, storage, and analysis of ingested data. A system includes a shared permissioned ledger comprising a plurality of independent ledger instances. The system includes a processor in communication with the shared permissioned ledger, wherein the processor matches a plurality of data entries stored on the shared permissioned ledger that each pertain to a transaction between a first client and a second client. The processor determines whether each of the plurality of data entries agree with each other to a threshold degree regarding the transaction between the first client and the second client.

Abstract: Systems and methods are disclosed for selecting a digital component for a user device based on data derived from connection parameters of the connection between the user device and an access point, without prompting the user for information. Connection parameters are extracted from access point data (e.g., geo-location parameters of the access point) that are specific to the access point and transformed into attributes of a user independently of requesting any submission of personal information from/about the user of the particular device. The attributes of the user are then used to generate a connection profile for the user. The connection profile can include the connection parameters as well as other derived attributes of the user. Based on the connection profile, a digital component is selected to be delivered to the user device.

Abstract: The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes.

Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology.

Abstract: The present invention relates to a stable pharmaceutical composition comprising a combination of chlordiazepoxide hydrochloride and clidinium bromide and one or more pharmaceutically acceptable excipients, wherein the composition is in the form of solid oral dosage forms like capsule and sachet. The technical challenges like undesirable impurities in dosage form were successfully controlled by using: a) low moisture excipients; and b) formulation development under controlled temperature and controlled humidity conditions. The formulations as per the present invention are stable and exhibit desired pharmaceutical technical attributes like assay and dissolution. The prepared formulations are useful for the treatment of gastrointestinal disorders and various other therapeutic indications as described herein.

Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology.

Abstract: System and methods for personalizing an application include an application server for hosting an application that is executed on a wireless device, the server being configured to monitor usage of a user interface including an interaction between a user of the application and one or more user interface elements and present an updated user interface comprising one or more additional user-interface elements based on the usage.

Abstract: Methods and systems for personalized trust recommendation based on a dynamic trust model. In an example embodiment, a trust framework can be derived from a set of use-case specific factors. Invasive data and non-invasive data can be collected from a user (or a group of users) based on activity data and profile data associated with the user. A dynamic trust profile can be created (or learned) based on the invasive data and the non-invasive data collected from the user. A recommended level of trustworthiness can be then provided to the user respect to a particular situation and/or entity (e.g. other users) within the trust framework based on the dynamic trust profile of the user and which is personalized for the user.

Abstract: The present invention relates to a solid oral pharmaceutical dosage form suitable for making a suspension comprising acid labile benzimidazole compounds and process for preparing the same. The prior art discloses various technical challenges associated with the granules for reconstitution into suspension like agglomeration of particles, viscosity and gelling time. The solid oral pharmaceutical dosage form of the present invention forms a homogeneous suspension upon admixing with an aqueous medium and exhibits desired technical attributes like viscosity, drug release, gelling time, dissolution and reduced adherence to nasogastric and gastric tubes.

Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the core is free of a surfactant. The prior art discloses restrictive formulation techniques and suggests higher amounts of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.

Abstract: Example analysis systems and methods are described. In one implementation, a system identifies a financial goal to be achieved and identifies financial account information associated with the financial goal. A plurality of insights are generated based on information from a plurality of data sources. A tool is implemented to generate at least one action based on the financial goal, the account information, and the insights. The system generates a recommendation based on the plurality of insights and the action, and automatically implements the recommendation to accomplish the financial goal.

Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the core is free of a surfactant. The prior art discloses restrictive formulation techniques and suggests higher amounts of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.

Abstract: The present invention relates to orally administered liquid pharmaceutical compositions of eslicarbazepine. The liquid compositions are in the form of ready to use suspension and suspension powder for reconstitution. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile and pH. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide physician with providing a more convenient and less cumbersome posology.

Abstract: The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes.

Abstract: The present application relates to pharmaceutical compositions comprising retinoic acid or its derivatives such as isotretinoin and processes for preparing thereof. It also provides methods for treating acne by administering such pharmaceutical composition to a patient in need thereof.

Abstract: Example collateral optimization systems and methods are described. In one implementation, a collateral optimization system includes a data ingestion engine that receives information associated with a trade and a collateral optimization module configured to optimize collateral associated with the trade. The collateral can be optimized for yield maximization or cost minimization. An asset settlement engine moves assets between multiple counterparties associated with the trade.